BR9509683A - Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto - Google Patents
Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um compostoInfo
- Publication number
- BR9509683A BR9509683A BR9509683A BR9509683A BR9509683A BR 9509683 A BR9509683 A BR 9509683A BR 9509683 A BR9509683 A BR 9509683A BR 9509683 A BR9509683 A BR 9509683A BR 9509683 A BR9509683 A BR 9509683A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- condition
- processes
- compounds
- pct
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000055 hyoplipidemic effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9423172A GB9423172D0 (en) | 1994-11-17 | 1994-11-17 | Hypolipidemic benzothiazepines |
| PCT/GB1995/002700 WO1996016051A1 (en) | 1994-11-17 | 1995-11-16 | Hypolipidemic benzothiazepines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9509683A true BR9509683A (pt) | 1997-09-16 |
Family
ID=10764525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9509683A BR9509683A (pt) | 1994-11-17 | 1995-11-16 | Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5998400A (pt) |
| EP (1) | EP0792268B1 (pt) |
| JP (1) | JP2868623B2 (pt) |
| KR (1) | KR970707111A (pt) |
| CN (1) | CN1059674C (pt) |
| AT (1) | ATE189891T1 (pt) |
| AU (1) | AU706325B2 (pt) |
| BR (1) | BR9509683A (pt) |
| CZ (1) | CZ147397A3 (pt) |
| DE (1) | DE69515183T2 (pt) |
| DK (1) | DK0792268T3 (pt) |
| ES (1) | ES2144151T3 (pt) |
| FI (1) | FI972085A0 (pt) |
| GB (1) | GB9423172D0 (pt) |
| GR (1) | GR3033450T3 (pt) |
| HU (1) | HUT77412A (pt) |
| MX (1) | MX9703546A (pt) |
| NO (1) | NO308470B1 (pt) |
| NZ (1) | NZ295426A (pt) |
| PL (1) | PL320093A1 (pt) |
| PT (1) | PT792268E (pt) |
| WO (1) | WO1996016051A1 (pt) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA956647B (en) * | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6268392B1 (en) | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6107494A (en) * | 1994-09-13 | 2000-08-22 | G.D. Searle And Company | Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6190513B1 (en) | 1997-05-14 | 2001-02-20 | Applied Materials, Inc. | Darkspace shield for improved RF transmission in inductively coupled plasma sources for sputter deposition |
| GB9704208D0 (en) * | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
| GB9800428D0 (en) * | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| AU776953B2 (en) | 1998-12-23 | 2004-09-30 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
| AU2157400A (en) | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications |
| CA2356422C (en) | 1998-12-23 | 2008-09-16 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
| EP1340510A1 (en) | 1998-12-23 | 2003-09-03 | G.D. Searle LLC. | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |
| PL348503A1 (en) | 1998-12-23 | 2002-05-20 | Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| CA2356607A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| WO2000038721A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| HUP0105409A3 (en) * | 1999-02-12 | 2004-11-29 | G D Searle Llc Chicago | 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake, use thereof and pharmaceutical compositions containing them |
| DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| SE0000772D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| JP2003528830A (ja) | 2000-03-10 | 2003-09-30 | ファルマシア・コーポレーション | テトラヒドロベンゾチエピン類の製造方法 |
| US20020183307A1 (en) * | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| EG26979A (en) * | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| NZ531796A (en) | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
| JP2005521653A (ja) | 2002-01-17 | 2005-07-21 | ファルマシア コーポレイション | 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物 |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| AU2003254354A1 (en) * | 2002-07-23 | 2004-02-09 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterol-reducing agent made of dietary fibre and cholesterol-reducing substances |
| US20040147774A1 (en) * | 2002-12-20 | 2004-07-29 | Aventis Pharma S.A. | Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid |
| DE10261067A1 (de) * | 2002-12-24 | 2004-08-05 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure |
| DE10261061A1 (de) * | 2002-12-24 | 2004-07-15 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| WO2006006740A1 (ja) * | 2004-07-14 | 2006-01-19 | Japan Tobacco Inc. | ３−アミノベンズアミド化合物及びバニロイド受容体１型(ｖｒ１)活性阻害剤 |
| NZ552086A (en) * | 2004-07-15 | 2009-12-24 | Japan Tobacco Inc | Fused benzamide compound and vanilloid receptor 1 (VR1) activity inhibitor |
| US7906508B2 (en) * | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| JP2012509891A (ja) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ，インク． | 肥満症及び糖尿病を治療するための胆汁酸再循環阻害剤 |
| WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| HUE030062T2 (en) | 2010-11-08 | 2017-04-28 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| PT2637646T (pt) | 2010-11-08 | 2016-08-17 | Albireo Ab | Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar |
| US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| EP2968262A1 (en) | 2013-03-15 | 2016-01-20 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease |
| CA2907230A1 (en) | 2013-03-15 | 2014-09-18 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CA3011565C (en) | 2016-02-09 | 2024-01-02 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| JP6954927B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| KR101844184B1 (ko) | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
| EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| CA3071182A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202015699A (zh) * | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
| BR112020024479A2 (pt) | 2018-06-20 | 2021-03-02 | Albireo Ab | hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| ES2937153T3 (es) | 2019-02-06 | 2023-03-24 | Albireo Ab | Compuestos de benzotiadiazepinas y su uso como moduladores de ácidos biliares |
| EP3921027B1 (en) * | 2019-02-06 | 2023-07-19 | Albireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| AU2020221834A1 (en) | 2019-02-12 | 2021-09-02 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency |
| EP4069361B1 (en) * | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2021110887A1 (en) | 2019-12-04 | 2021-06-10 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| HUE065571T2 (hu) | 2019-12-04 | 2024-06-28 | Albireo Ab | Benzotia(di)azepin vegyületek és alkalmazásuk epesav modulátorként |
| ES2972045T3 (es) | 2019-12-04 | 2024-06-10 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| DK4069360T3 (da) | 2019-12-04 | 2024-02-26 | Albireo Ab | Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| AR120683A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como ácido biliar |
| CN116157389A (zh) | 2020-08-03 | 2023-05-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| WO2022029101A1 (en) | 2020-08-03 | 2022-02-10 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| WO2024008766A1 (en) | 2022-07-05 | 2024-01-11 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US20240207286A1 (en) | 2022-12-09 | 2024-06-27 | Albireo Ab | Asbt inhibitors in the treatment of renal diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59231018A (ja) * | 1983-06-10 | 1984-12-25 | Tanabe Seiyaku Co Ltd | 抗脂血剤 |
| ATE116643T1 (de) * | 1989-04-28 | 1995-01-15 | Tanabe Seiyaku Co | Verfahren zur herstellung von 1,5- benzothiazepinderivaten. |
| GB2255937B (en) * | 1991-05-21 | 1994-11-09 | Andrew Thomas Kinnaird | Sailboards |
| GB9111376D0 (en) * | 1991-05-25 | 1991-07-17 | Boots Co Plc | Therapeutic agents |
| GB9203347D0 (en) * | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| KR950704280A (ko) * | 1992-12-11 | 1995-11-17 | 베르너 발데크 | 벤즈아제피논 유도체(Benzazepinone Derivatives) |
| IL108634A0 (en) * | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| IL108633A (en) * | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
| GB9307017D0 (en) * | 1993-04-02 | 1993-05-26 | Bp Chem Int Ltd | Control of ammonia emission and odour |
| JPH09501915A (ja) * | 1993-08-06 | 1997-02-25 | スミスクライン・ビーチャム・コーポレイション | エンドセリン受容体アンタゴニスト |
| ZA956647B (en) * | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| GB9704208D0 (en) * | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
-
1994
- 1994-11-17 GB GB9423172A patent/GB9423172D0/en active Pending
-
1995
- 1995-11-16 DK DK95937940T patent/DK0792268T3/da active
- 1995-11-16 DE DE69515183T patent/DE69515183T2/de not_active Expired - Fee Related
- 1995-11-16 HU HU9702189A patent/HUT77412A/hu unknown
- 1995-11-16 ES ES95937940T patent/ES2144151T3/es not_active Expired - Lifetime
- 1995-11-16 WO PCT/GB1995/002700 patent/WO1996016051A1/en not_active Application Discontinuation
- 1995-11-16 MX MX9703546A patent/MX9703546A/es not_active IP Right Cessation
- 1995-11-16 PT PT95937940T patent/PT792268E/pt unknown
- 1995-11-16 CN CN95196304A patent/CN1059674C/zh not_active Expired - Fee Related
- 1995-11-16 EP EP95937940A patent/EP0792268B1/en not_active Expired - Lifetime
- 1995-11-16 BR BR9509683A patent/BR9509683A/pt not_active IP Right Cessation
- 1995-11-16 NZ NZ295426A patent/NZ295426A/en unknown
- 1995-11-16 PL PL95320093A patent/PL320093A1/xx unknown
- 1995-11-16 AT AT95937940T patent/ATE189891T1/de not_active IP Right Cessation
- 1995-11-16 JP JP51666196A patent/JP2868623B2/ja not_active Expired - Fee Related
- 1995-11-16 CZ CZ971473A patent/CZ147397A3/cs unknown
- 1995-11-16 AU AU38762/95A patent/AU706325B2/en not_active Ceased
- 1995-11-16 US US08/836,405 patent/US5998400A/en not_active Expired - Fee Related
-
1997
- 1997-05-15 FI FI972085A patent/FI972085A0/fi unknown
- 1997-05-16 KR KR1019970703298A patent/KR970707111A/ko not_active Application Discontinuation
- 1997-05-16 NO NO972261A patent/NO308470B1/no unknown
-
2000
- 2000-05-19 GR GR20000401138T patent/GR3033450T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GR3033450T3 (en) | 2000-09-29 |
| FI972085A (fi) | 1997-05-15 |
| GB9423172D0 (en) | 1995-01-04 |
| ES2144151T3 (es) | 2000-06-01 |
| JPH11500102A (ja) | 1999-01-06 |
| NZ295426A (en) | 1997-10-24 |
| NO972261L (no) | 1997-07-16 |
| ATE189891T1 (de) | 2000-03-15 |
| WO1996016051A1 (en) | 1996-05-30 |
| JP2868623B2 (ja) | 1999-03-10 |
| NO972261D0 (no) | 1997-05-16 |
| NO308470B1 (no) | 2000-09-18 |
| CZ147397A3 (en) | 1997-11-12 |
| DE69515183D1 (de) | 2000-03-30 |
| FI972085A0 (fi) | 1997-05-15 |
| KR970707111A (ko) | 1997-12-01 |
| HUT77412A (hu) | 1998-04-28 |
| DE69515183T2 (de) | 2000-08-17 |
| CN1059674C (zh) | 2000-12-20 |
| PT792268E (pt) | 2000-06-30 |
| AU706325B2 (en) | 1999-06-17 |
| AU3876295A (en) | 1996-06-17 |
| EP0792268A1 (en) | 1997-09-03 |
| MX9703546A (es) | 1997-08-30 |
| CN1164230A (zh) | 1997-11-05 |
| DK0792268T3 (da) | 2000-07-31 |
| PL320093A1 (en) | 1997-09-15 |
| EP0792268B1 (en) | 2000-02-23 |
| US5998400A (en) | 1999-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9509683A (pt) | Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto | |
| MX9700890A (es) | 1, 4-benzotiazepina-1, 1-dioxidos hipolipidemicos. | |
| TR200001816T2 (tr) | Hipolipidemik benzotiyazepin bileşikleri | |
| ZA953469B (en) | New compound | |
| DE69514813D1 (en) | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren | |
| DE69616749D1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
| ES2162934T3 (es) | Derivados de fenil xantina. | |
| MX9300821A (es) | Compuestos hipolipidemicos. | |
| DE69529690D1 (de) | Diaryl-2(5h)-fuaranone als cox-2-inhibitoren | |
| BR9505938A (pt) | Composto processo para sua preparação processos para tratamento e prevenção de doenças processo de elevação dos níveis de HDL plasmático e composiç o farmacêutica | |
| LV12632A (lv) | Pyrazoline derivatives their preparation and application as medicaments | |
| BR9808812A (pt) | Composição compreendendo partìculas cristalinas, finamente divididas de budesonida | |
| DE59409312D1 (de) | Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten | |
| ZA865192B (en) | New carboxylic acid derivatives,processes for the preparation thereof,the use thereof and pharmaceutical compositions containing them | |
| BR9507677A (pt) | Composto composição farmacéutica processo para a profilaxia ou para o tratamento de condições associadas à inflamação à artrite ou à dor em um mamifero uso do composto processo para a preparação do composto e novo intermediário | |
| DE69432124D1 (de) | Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes | |
| BR9502072A (pt) | Composto metodo para o tratamento de uma condiçao médica e composiçao farmaceutica | |
| ATE110568T1 (de) | Pharmazeutisches präparat zur behandlung des katarakts. | |
| ATE194076T1 (de) | Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen | |
| ATE190484T1 (de) | Arzneimittel zur behandlung von durch babesia verursachten protozoeninfektionen | |
| NZ320522A (en) | Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds | |
| BR0010338A (pt) | Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto | |
| DE69109293D1 (de) | Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA12 | Dismissal: dismissal - article 216, par. 2 of industrial property law | ||
| FA12 | Dismissal: dismissal - article 216, par. 2 of industrial property law | ||
| HKFN | Application deemed withdrawn (deleted) | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 12A, 13A, 14A, 15A E 16A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E16A ANUIDADES. |